Diagnostic Accuracy of BRAF Immunohistochemistry in Colorectal Cancer: a Meta-Analysis and Diagnostic Test Accuracy Review.

Pyo, Jung-Soo; Sohn, Jin Hee; Kang, Guhyun
Pathology oncology research : POR
2016May ; 8 ( 5 ) :.
ÀúÀÚ »ó¼¼Á¤º¸
Pyo, Jung-Soo - Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunanro, Jongno-gu, Seoul, 03181, Republic of Korea.
Sohn, Jin Hee - Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunanro, Jongno-gu, Seoul, 03181, Republic of Korea. jhpath.sohn@samsung.com.
Kang, Guhyun - Department of Pathology, Inje University Sanggye Paik Hospital, Seoul, Republic of Korea.
ABSTRACT
The aim of this study was to evaluate the concordance between the BRAF (V600E) mutation test and immunohistochemistry (IHC) and to evaluate the diagnostic accuracy of BRAF IHC for colorectal cancer (CRC) through a systematic review, meta-analysis, and diagnostic test accuracy review. The current study included 1021 CRCs from eight eligible studies. The concordance rates were investigated between BRAF IHC and the mutation test. In addition, diagnostic test accuracy review was conducted and calculated using the value of area under curve (AUC) on the summary receiver operating characteristic (SROC) curve. The positive rate of BRAF IHC was 30.5?% (range; 13.2-66.2?%), and the BRAF mutation was found in 30.2?% (range; 11.7-66.2?%). The overall concordance rate between BRAF IHC and the mutation test was 0.944 (95?% confidence interval (CI) 0.873-0.977). In the BRAF IHC-positive and -negative groups, the concordance rates between BRAF IHC and the mutation test were 0.895 (95?% CI 0.800-0.945) and 0.956 (95?% CI 0.878-0.985), respectively. The pooled sensitivity and specificity were 0.94 (95?% CI 0.91-0.96) and 0.96 (95?% CI 0.95-0.98), respectively. The diagnostic odds ratio was 272.86 (95?% CI 46.11-1614.88), and the value of AUC on SROC curve was 0.9846. Taken together, our results suggest that BRAF IHC is strongly concordant with the BRAF mutation test and has high diagnostic accuracy in BRAF mutation analysis of CRCs. Further cumulative studies on detailed evaluation criteria are needed before application in daily practice.
keyword
BRAF V600E immunohistochemistry; Colorectal cancer; Concordance; Diagnostic accuracy; Meta-analysis
¸µÅ©

ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
BRAF IHC is strongly concordant with the BRAF mutation test and has high diagnostic accuracy in BRAF mutation analysis of CRCs.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
10.1007/s12253-016-0077-2
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå